Results 21 to 30 of about 30,793 (265)
Progress in Neoantigen Targeted Cancer Immunotherapies
Frontiers in Cell and Developmental Biology, 2020 Immunotherapies that harness the immune system to kill cancer cells have showed significant therapeutic efficacy in many human malignancies. A growing number of studies have highlighted the relevance of neoantigens in recognizing cancer cells by ...
Xue-Jiao Han +5 more
doaj +1 more source
neoANT-HILL: an integrated tool for identification of potential neoantigens
BMC Medical Genomics, 2020 Background Cancer neoantigens have attracted great interest in immunotherapy due to their capacity to elicit antitumoral responses. These molecules arise from somatic mutations in cancer cells, resulting in alterations on the original protein ...
Ana Carolina M. F. Coelho +5 more
doaj +1 more source
The Role of Neoantigens in Cancer Immunotherapy
Frontiers in Oncology, 2021 Somatic mutation-derived neoantigens, expressed only on tumor cells, may elicit antitumor T-cell responses in cancer immunotherapies with minimal immune tolerance.
Yueting Zhu, Jiyan Liu, Jiyan Liu
doaj +1 more source
Neoantigen quality, not quantity [PDF]
Science Translational Medicine, 2019 Prioritizing expressed clonal neoantigens in genes required for cancer cell survival may reduce the likelihood of resistance to neoantigen therapies.
Nicholas McGranahan, Charles Swanton
openaire +3 more sources
Determinants for Neoantigen Identification [PDF]
Frontiers in Immunology, 2019 All tumors accumulate genetic alterations, some of which can give rise to mutated, non-self peptides presented by human leukocyte antigen (HLA) molecules and elicit T-cell responses. These immunogenic mutated peptides, or neoantigens, are foreign in nature and display exquisite tumor specificity.
Andrea Garcia-Garijo +2 more
openaire +3 more sources
Genome Biology, 2023 Background Neoantigens are critical for anti-tumor immunity and have been long-envisioned as promising therapeutic targets. However, current neoantigen analyses mostly focus on single nucleotide variations (SNVs) and indel mutations and seldom consider ...
Yang Shi, Biyang Jing, Ruibin Xi
doaj +1 more source
Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
Current Oncology, 2023 Multiple myeloma (MM) is malignant disease characterized by the clonal proliferation of plasma cells in the bone marrow, leading to anemia, immunosuppression, and other symptoms, that is generally hard to treat. In MM, the immune system is likely exposed
Valentina Urzì Brancati +4 more
doaj +1 more source
Evolutionary dynamics of neoantigens in growing tumours
, 2019 Cancer evolution is driven by the acquisition of somatic mutations that provide cells with a beneficial phenotype in a changing microenvironment. However, mutations that give rise to neoantigens, novel cancer–specific peptides that elicit an immune ...
Werner, B +23 more
core +2 more sources
The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
iScience, 2019 Summary: Compared with SNV&indel-based neoantigens, fusion-based neoantigens are not well characterized. In the present study, we performed a comprehensive analysis of the landscape of tumor fusion neoantigens in cancer and proposed a score scheme to ...
Zhiting Wei +6 more
doaj +1 more source
Cancer Medicine, 2023 Objectives Intratumor heterogeneity (ITH) is an important factor for clinical outcomes in patients with multiple myeloma (MM). High ITH has been proven to be a key reason for tumor immune escape and treatment resistance.
Yue Wang +4 more
doaj +1 more source